Press release
Psoriatic Arthritis Therapeutics Market Size in 7MM is expected to grow by 2034, estimates DelveInsight
DelveInsight's 'Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast - 2034' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the psoriatic arthritis therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.Discover Key Insights into the Psoriatic Arthritis Market with DelveInsight's In-Depth Report @ Psoriatic Arthritis Market Size [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from Psoriatic Arthritis Market Research Report
* In November 2024:- AbbVie- A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2).
* According to DelveInsight's analysis, Psoriatic Arthritis was observed to affect females more frequently than males. In 2023, females accounted for approximately 15% more PsA cases compared to males.
* DelveInsight's analysis indicates that in 2023, the majority of Psoriatic Arthritis cases were of moderate severity, comprising approximately 60% of cases, followed by severe and mild forms.
* In the US in 2023, the age group 50-59 years had the highest prevalence of Psoriatic Arthritis, while the 18-29 age group had the lowest number of cases.
* According to DelveInsight's analysis, in 2023, Germany had the highest number of Psoriatic Arthritis cases among the EU4 countries and the UK, while Spain reported the lowest.
* The National Psoriatic Foundation reports that approximately 1 in 3 individuals, or 30%, with psoriasis develop Psoriatic Arthritis, affecting up to 2.4 million Americans. PsA can occur at any age.
* According to the study by Brent et al. (2024), the prevalence of psoriatic arthritis among individuals with psoriasis was 1.7% at 5 years, 3.1% at 10 years, 5.1% at 20 years, and 20.5% at 30 years. Overall, the prevalence of psoriatic arthritis in psoriasis patients is 19.7%, with 21.6% in adults and 3.3% in children.
* The leading Psoriatic Arthritis Companies such as AbbVie, Amgen, Johnson & Johnson, Bristol, Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, and UCB Biosciences Inc., and others.
* Promising Psoriatic Arthritis Therapies such as NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg , and others.
Stay ahead in the Psoriatic Arthritis Therapeutics Market with DelveInsight's Strategic Report @ Psoriatic Arthritis Market Outlook [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psoriatic Arthritis Epidemiology Segmentation in the 7MM
* Psoriatic Arthritis prevalent cases
* Psoriatic Arthritis diagnosed cases
* Psoriatic Arthritis gender-specific cases
* Psoriatic Arthritis age-specific cases
* Psoriatic Arthritis severity-specific cases
Download the report to understand which factors are driving Psoriatic Arthritis epidemiology trends @ Psoriatic Arthritis Prevalence [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psoriatic Arthritis Emerging Drugs
* Bimekizumab (UCB Biopharma) is an investigational, humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17F has overlapping biology with IL-17A and drives inflammation independently of IL-17A.
* Tildrakizumab (Sun Pharmaceutical) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in the US.
Psoriatic Arthritis Drugs Market
The Psoriatic Arthritis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Psoriatic Arthritis signaling in Psoriatic Arthritis are likely to uncover new therapeutic targets and further expand treatment options for patients.
Psoriatic Arthritis Treatment Market Landscape
The Psoriatic Arthritis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Psoriatic Arthritis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
Get In-Depth Knowledge on Psoriatic Arthritis Market Trends and Forecasts with DelveInsight @ Psoriatic Arthritis Treatment Market [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psoriatic Arthritis Companies
AbbVie, Amgen, Johnson & Johnson, Bristol, Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, and UCB Biosciences Inc., and others.
Scope of the Psoriatic Arthritis Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Psoriatic Arthritis Companies- AbbVie, Amgen, Johnson & Johnson, Bristol, Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, and UCB Biosciences Inc., and others.
* Psoriatic Arthritis Therapies- NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, and others.
* Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis Market Drivers and Barriers
* Psoriatic Arthritis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Unlock Strategic Insights with DelveInsight's Comprehensive Psoriatic Arthritis Market Report @ Psoriatic Arthritis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Report Introduction
3. Psoriatic Arthritis Market Overview at a Glance
4. Executive Summary of Psoriatic Arthritis
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Patient Journey of Psoriatic Arthritis
8. Marketed Products
9. Emerging Therapies
10. Other Assets
11. Psoriatic Arthritis (PsA): Seven Major Market Analysis
12. SWOT Analysis
13. KOL Views
14. Unmet Needs
15. Market Access
16. Acronyms and Abbreviations
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriatic-arthritis-therapeutics-market-size-in-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriatic Arthritis Therapeutics Market Size in 7MM is expected to grow by 2034, estimates DelveInsight here
News-ID: 3779347 • Views: …
More Releases from ABNewswire
Leavitt Peak Press Announces the Release of the Guardians: Paporia Two by F. Tho …
Leavitt Peak Press is proud to announce the release of The Guardians: Paporia Two, the action-packed sequel to The Guardians: Escape from Tirgonia by military veteran and author F. Thomas Jones. This thrilling continuation of the Guardians saga dives deeper into a galactic conflict that pits courage, loyalty, and wisdom against overwhelming odds.
Now in the second year of war with the ruthless Tirogian Empire, The Guardians face their greatest challenge…
Jiaropack Expands Global Footprint and U.S. Manufacturing to Strengthen Supply C …
Image: https://www.abnewswire.com/upload/2025/10/e8885cfe8ab28873224866f01a36a3fa.jpg
California, USA - Jiaropack, a brand of Global Store Supply, Inc., a global leader in packaging, industrial, and shipping materials, today announced a major expansion of its U.S. manufacturing and logistics network to further enhance supply chain stability and nationwide delivery efficiency, providing faster and more reliable products and services to customers worldwide.
To enhance supply chain security and consistent product delivery, Jiaropack has recently purchased several Texas-based plastic product…
Clostridioides Difficile Infection Market Size in the 7MM was ~USD 500 million i …
DelveInsight's "Clostridioides Difficile Infection Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Clostridioides Difficile Infection, historical and forecasted epidemiology as well as the Clostridioides Difficile Infection therapeutics market trends in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Clostridioides Difficile Infection Market with DelveInsight's In-Depth Report @ Clostridioides Difficile Infection Treatment Market Size…
Triple Negative Breast Cancer Market Set for Robust Growth Through 2034Innovativ …
Driven by rise of immunotherapies, antibody-drug conjugates, and precision-targeted approaches, TNBC market is projected to expand from USD 4.7 billion in 2025 to USD 7.1 billion by 2034, marking a CAGR of 4.7% across the 7MM. Leading players like AstraZeneca, Pfizer, Gilead Sciences, BioNTech, Astellas Pharma are at forefront, advancing next-generation therapies such as ADC platforms, checkpoint inhibitors, and novel vaccines that aim to improve survival outcomes and redefine patient…
More Releases for Psoriatic
Psoriatic Arthritis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Psoriatic Arthritis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Psoriatic Arthritis Research. Learn more about…
Psoriatic Arthritis Treatment: A New Era of Relief
The Business Research Company recently released a comprehensive report on the Global Psoriatic Arthritis Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The psoriatic arthritis treatment…
Psoriatic Arthritis Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Psoriatic Arthritis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Psoriatic Arthritis Pipeline Report
• Over 20+…
Psoriatic Arthritis Treatment Market - Unleash the Power of Relief: Elevating Tr …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Psoriatic Arthritis Treatment Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Psoriatic Arthritis Treatment provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes…
Psoriatic Arthritis Treatment Market Size, CAGR | Growth - 2030
Exclusive Report by Ameco Research: Psoriatic Arthritis Treatment Market Size Projected to Reach USD 26 Billion by 2030, Growing at 9.60% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Psoriatic Arthritis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality…
Psoriatic Arthritis Treatment Market Growth Framework 2025
Global Psoriatic Arthritis Treatment Market: Overview
The demand within the global psoriatic arthritis treatment market has been rising on account of advancements in the field of healthcare and biosimilar analysis. The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called…
